Dr. Scott Shell is a cancer diagnostics expert with extensive experience advancing molecular testing technologies that support both early cancer detection and ongoing disease monitoring. Over more than 15 years across leading diagnostic and clinical research organizations, he has focused on translating complex biomarker and molecular assay science into practical tools that strengthen clinical decision-making and improve patient outcomes.

Dr. Shell has held scientific affairs and oncology diagnostics roles at Saga Diagnostics, Guardant Health, Agena Bioscience, Asuragen, and IQVIA laboratory divisions, contributing to the development and implementation of genomic, liquid biopsy, and molecular platforms used in clinical trials and patient care settings.

A strong advocate for cancer screening and vigilance in disease monitoring, he routinely encourages those around him to stay current with guideline-based testing and helps clarify available diagnostic options. Catching cancer early is a critical strategy to fighting the disease. His awareness of screening gaps—particularly in communities facing access barriers—drives his commitment to clearer, more approachable health information.

As incoming Chief Operations Officer of HopeScan, Dr. Shell brings scientific rigor and operational focus to advancing the organization’s mission: expanding awareness of screening and monitoring options, strengthening health literacy, and helping reduce cancer burden through accessible, trustworthy guidance.

Dr. Shell obtained his PhD in Molecular Biology from the University of Pittsburgh School of Medicine, and his BS in Biochemistry from Arizona State University.